炎症性腸疾患の世界市場予測（2022年～2028年）

世界の炎症性腸疾患（IBD）の市場規模は、予測期間中に5.6%の大幅なCAGRで成長すると予測されています。

IBD治療の強力なパイプライン製品の存在と臨床試験活動の拡大が、市場成長を促進する主要な要因の一つです。

当レポートでは、世界の炎症性腸疾患市場について調査分析し、市場概要、セグメント・地域別の市場分析、競合情勢、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

• 調査範囲
• アナリストの洞察と現在の市場動向

第3章 競合情勢

• 主要企業分析
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の開発
• 主要戦略分析
• COVID-19が主要企業に与える影響

第4章 市場の内訳

• 世界の炎症性腸疾患（IBD）市場：疾患タイプ別
  • 潰瘍性大腸炎
  • クローン病
• 世界の炎症性腸疾患（IBD）市場：診断方法別
  • 血液・便検査
  • 内視鏡検査
  • 超音波
  • X線
• 世界の炎症性腸疾患（IBD）市場：治療アプローチ別
  • 手術
  • 抗炎症薬の投与

第5章 地域分析

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • スペイン
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 世界のその他の地域

第6章 企業プロファイル

• Accesa Labs
• Amag Pharmaceuticals
• American Regent, Inc.
• CSC Pharmaceuticals
• Daiichi Sankyo
• Emisphere Technologies Inc.
• Empower Pharmacy
• Endo Pharmaceuticals Inc.
• Galenica
• Glaxosmithkline
• Laboratory Corp. of America Holdings
• Mercator Pharma
• Panacea Biotec Ltd.
• Pharmacosmos
• Rpg Life Sciences Ltd.
• Sanofi Sa
• Takeda Pharmaceutical Co. Ltd.

LIST OF TABLES

• 1. GLOBAL IBD MARKET RESEARCH AND ANALYSIS BYDISEASE TYPE, 2021-2028 ($ MILLION)
• 2. GLOBALULCERATIVE COLITISMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
• 3. GLOBALCROHN'S DISEASESMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
• 4. GLOBAL IBD MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2021-2028 ($ MILLION)
• 5. GLOBAL BLOOD AND STOOL TESTS IN IBDMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
• 6. GLOBAL ENDOSCOPIES IN IBDMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
• 7. GLOBAL ULTRASOUND IN IBDMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
• 8. GLOBAL X-RAYS IN IBDMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
• 9. GLOBAL IBD MARKET RESEARCH AND ANALYSIS BY TREATMENT APPROACH, 2021-2028 ($ MILLION)
• 10. GLOBAL SURGERY FOR DRUG DISCOVERY AND DEVELOPMENTMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
• 11. GLOBAL ANTI-INFLAMMATORY DRUG ADMINISTRATION FOR DRUG DISCOVERY AND DEVELOPMENTMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
• 12. GLOBAL IBD MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
• 13. NORTH AMERICAN IBD MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
• 14. NORTH AMERICAN IBD MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2021-2028 ($ MILLION)
• 15. NORTH AMERICAN IBD MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2021-2028 ($ MILLION)
• 16. NORTH AMERICAN IBD MARKET RESEARCH AND ANALYSIS BY TREATMENT APPROACH, 2021-2028 ($ MILLION)
• 17. EUROPEAN IBD MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
• 18. EUROPEAN IBD MARKET RESEARCH AND ANALYSIS BY DISEASE TYPW, 2021-2028 ($ MILLION)
• 19. EUROPEAN IBD MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2021-2028 ($ MILLION)
• 20. EUROPEAN IBD MARKET RESEARCH AND ANALYSIS BY TREATMENT APPROACH, 2021-2028 ($ MILLION)
• 21. ASIA-PACIFIC IBD MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
• 22. ASIA-PACIFIC IBD MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2021-2028 ($ MILLION)
• 23. ASIA-PACIFIC IBD MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2021-2028 ($ MILLION)
• 24. ASIA-PACIFIC IBD MARKET RESEARCH AND ANALYSIS BY TREATMENT APPROACH, 2021-2028 ($ MILLION)
• 25. REST OF THE WORLD IBD MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
• 26. REST OF THE WORLD IBD MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2021-2028 ($ MILLION)
• 27. REST OF THE WORLD IBD MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2021-2028 ($ MILLION)
• 28. REST OF THE WORLD IBD MARKET RESEARCH AND ANALYSIS BY TREATMENT APPROACH, 2021-2028 ($ MILLION)

LIST OF FIGURES

• 1. IMPACT OF COVID-19 ON GLOBAL IBD MARKET, 2021-2028 ($ MILLION)
• 2. IMPACT OF COVID-19 ON GLOBAL IBD MARKET BY SEGMENT, 2021-2028 ($ MILLION)
• 3. RECOVERY OF GLOBAL IBD MARKET, 2022-2028 (%)
• 4. GLOBAL IBD MARKET SHARE BY DISEASE TYPE, 2021 VS 2028 (%)
• 5. GLOBALULCERATIVE COLITIS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)GLOBALCROHN'S DISEASESMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 6. GLOBAL IBD MARKET SHARE BY DIAGNOSIS METHOD, 2021 VS 2028 (%)
• 7. GLOBAL BLOOD AND STOOL TESTS IN IBDMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 8. GLOBAL ENDOSCOPIES IN IBDMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 9. GLOBAL ULTRASOUND IN IBDMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 10. GLOBAL X-RAYS IN IBDMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 11. GLOBAL IBD MARKET SHARE BY TREATMENT APPROACH, 2021 VS 2028 (%)
• 12. GLOBAL SURGERY FOR DRUG DISCOVERY AND DEVELOPMENTMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 13. GLOBALANTI-INFLAMMATORY DRUG ADMINISTRATIONFOR DRUG DISCOVERY AND DEVELOPMENTMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 14. GLOBAL IBD MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 15. US IBD MARKET SIZE, 2021-2028 ($ MILLION)
• 16. CANADA IBD MARKET SIZE, 2021-2028 ($ MILLION)
• 17. UK IBD MARKET SIZE, 2021-2028 ($ MILLION)
• 18. FRANCE IBD MARKET SIZE, 2021-2028 ($ MILLION)
• 19. GERMANY IBD MARKET SIZE, 2021-2028 ($ MILLION)
• 20. ITALY IBD MARKET SIZE, 2021-2028 ($ MILLION)
• 21. SPAIN IBD MARKET SIZE, 2021-2028 ($ MILLION)
• 22. REST OF EUROPE IBD MARKET SIZE, 2021-2028 ($ MILLION)
• 23. INDIA IBD MARKET SIZE, 2021-2028 ($ MILLION)
• 24. CHINA IBD MARKET SIZE, 2021-2028 ($ MILLION)
• 25. JAPAN IBD MARKET SIZE, 2021-2028 ($ MILLION)
• 26. SOUTH KOREA IBD MARKET SIZE, 2021-2028 ($ MILLION)
• 27. REST OF ASIA-PACIFIC IBD MARKET SIZE, 2021-2028 ($ MILLION)
• 28. REST OF THE WORLD IBD MARKET SIZE, 2021-2028 ($ MILLION)

Global Inflammatory Bowel Disease (IBD) Market Size, Share & Trends Analysis Report by Disease Type (Ulcerative Colitis and Crohn's Disease), by Diagnosis Method (Blood And Stool Tests, Endoscopies, Ultrasound, and X-Rays), and by Treatment Approach (Surgery and Anti-Inflammatory Drug Administration) Forecast Period (2022-2028)

The global IBD market is anticipated to grow at a substantial CAGR of 5.6% during the forecast period. Growing clinical trial activities coupled with the presence of strong pipeline products for treating IBD are some of the major factors that are driving the market growth. According to the US National Library of Medicine, as of October 2019, there are a total of 730 clinical trials including drug development, observational studies, and others related to IBD. Additionally, out of these 268 clinical trials were conducted in the US only.

The global IBD market is segmented based on disease type, diagnosis method, and treatment approach. Based on the disease type, the market is sub-segmented into ulcerative colitis and Crohn's disease. Based on the diagnosis method, the market is sub-segmented into blood and stool tests, endoscopies, ultrasound, and X-rays. Based on the treatment approach, the market is further augmented into surgery and anti-inflammatory drug administration. The surgery segment includes surgery for Crohn's and ulcerative diseases. Further, the anti-inflammatory drug administration comprises steroids, immunosuppressants, biological drugs, amino salicylates, and others (antibiotics and symptomatic drugs). Among the disease type, the Crohn's disease segment is anticipated to hold a prominent share in the global IBD market, owing to the rapidly increasing incidence rate, and prescription rate of biologics. According to Crohn's and Colitis Foundation, around 25% of patients with Crohn's disease in the US have been prescribed biologics every year.

Geographically the global IBD market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America holds a prominent market for IBD owing toa large number of patients in the region coupled with the most advanced healthcare infrastructure. On contrary, the Asia-Pacific regional market for IBD treatment is anticipated to grow at the fastest CAGR over the forecast period. The increasing prevalence of Crohn's and ulcerative colitis along with rapidly rising novel drug approval are expected to drive the market. According to a study published by NCBI, in 2019, the prevalence of Crohn's disease is higher in men compared to women. The highest incidence of IBD was observed in East Asian countries including Japan, Korea, China, and others.

The major companies serving the global IBD market include Abbott Laboratories, Amgen, Inc, AstraZeneca PLC, Baxter International Inc., Bristol-Myers Squibb Company, Cosmo pharmaceuticals, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in February 2022, the Indian Council of Medical Research (ICMR) launched IBD NutriCare Application for IBD patients on the occasion of World Inflammatory Bowel Disease Day. This digital health platform for tele-nutrition provides a potential tool for improving the patient care in IBD.

Research Methodology

The market study of the global IBD market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

Financial reports of companies involved in the market.

Whitepapers, research papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Inflammatory Bowel Disease (IBD)Market Research and Analysis by Disease Type.

Global Inflammatory Bowel Disease (IBD)Market Research and Analysis by Diagnosis Method.

Global Inflammatory Bowel Disease (IBD)Market Research and Analysis by Treatment Approach.

The Report Covers

Comprehensive research methodology of the global inflammatory bowel disease (IBD) market.

This report also includes a detailed and extensive market overview with key analyst insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the global inflammatory bowel disease (IBD) market.

Insights about market determinants that are stimulating the global customer inflammatory bowel disease (IBD) market.

Detailed and extensive market segments with the regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Inflammatory Bowel Disease (IBD) Market
• Recovery Scenario of Global Inflammatory Bowel Disease (IBD)Market
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. ByRegion

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
  • 3.1.1. Overview
  • 3.1.2. Financial Analysis
  • 3.1.3. SWOT Analysis
  • 3.1.4. Recent Developments
• 3.2. Key Strategy Analysis
• 3.3. Impact of COVID-19 on Key Players

4. Market Segmentation

• 4.1. Global Inflammatory Bowel Disease (IBD) Market by Disease Type
  • 4.1.1. Ulcerative Colitis
  • 4.1.2. Crohn's Disease
• 4.2. Global Inflammatory Bowel Disease (IBD) Market by Diagnosis Method
  • 4.2.1. Blood and Stool Tests
  • 4.2.2. Endoscopies
  • 4.2.3. Ultrasound
  • 4.2.4. X-Rays
• 4.3. Global Inflammatory Bowel Disease (IBD) Market by Treatment Approach
  • 4.3.1. Surgery
    • 4.3.1.1. Surgery For Crohn's Disease
    • 4.3.1.2. Surgery For Ulcerative Colitis
  • 4.3.2. Anti- Inflammatory Drug Administration
    • 4.3.2.1. Steroids
    • 4.3.2.2. Immunosuppressants
    • 4.3.2.3. Biological Drugs
    • 4.3.2.4. Aminosalicylates
    • 4.3.2.5. Others (Antibiotics, Symptomatic Drugs)

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World

6. Company Profiles

• 6.1. Accesa Labs
• 6.2. Amag Pharmaceuticals
• 6.3. American Regent, Inc.
• 6.4. CSC Pharmaceuticals
• 6.5. Daiichi Sankyo
• 6.6. Emisphere Technologies Inc.
• 6.7. Empower Pharmacy
• 6.8. Endo Pharmaceuticals Inc.
• 6.9. Galenica
• 6.10. Glaxosmithkline
• 6.11. Laboratory Corp. of America Holdings
• 6.12. Mercator Pharma
• 6.13. Panacea Biotec Ltd.
• 6.14. Pharmacosmos
• 6.15. Rpg Life Sciences Ltd.
• 6.16. Sanofi Sa

17. Takeda Pharmaceutical Co. Ltd.